About this trial
Very few studies have investigated TAE as a treatment for goiter with compressive symptoms. What is the efficacy and safety of TAE for the treatment of compressive goiters in a population ineligible for or refusing standard therapy? This is a prospective interventional cohort study that will allow us to standardize imaging by improving quality data collection and fellow-up to assess the efficacy of TAE for compressive symptoms of nodular goiters. Not only to corroborate current emerging results but clearly define the expected results for this technique.
Eligibility criteria
Qualifiers
Patient with compressive symptoms or significant tracheal or oesophageal compression at risk of causing symptoms attributed to a goiter AND
Ineligible for surgery/ablative treatments or preference for TAE over other treatments AND
TiRADS category 1, 2, 3 or 4 AND
Bethesda categories I or III on 2 different biopsies OR Bethesda II on one biopsy AND
Disqualifiers
Comorbidities precluding endovascular procedure OR
TiRADS category 5 OR
Bethesda categories IV, V, VI on biopsy OR
Refusal of the patient to participate OR
Trial design
Treatments tested in this trial
- Thyroid Artery Embolization